SAN DIEGO--(BUSINESS WIRE)--Dec. 15, 2005--Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, is pleased to announce that AstraZeneca Pharmaceuticals LP (NYSE:AZN) has licensed access to its Target Informatics Platform(TM). Under the agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty’s Target Informatics Platform (TIP(TM)) and EVE(TM) Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs. Financial terms were not disclosed.
